Van de Velde Sarah, Van Bergen Tine, Vandewalle Evelien, Moons Lieve, Stalmans Ingeborg
Department of Neurosciences, Laboratory of Ophthalmology, KU Leuven, Leuven, Belgium.
Department of Neurosciences, Laboratory of Ophthalmology, KU Leuven, Leuven, Belgium; Department of Ophthalmology, University Hospitals Leuven (UZ Leuven), Leuven, Belgium.
Prog Brain Res. 2015;221:319-40. doi: 10.1016/bs.pbr.2015.05.002. Epub 2015 Jun 30.
Glaucoma is a neurodegenerative disease and is the second most important cause of irreversible blindness. Filtration surgery remains the most effective therapy to reduce intraocular pressure in glaucoma patients. The main determinant of long-term surgical success is the healing response. Excessive postoperative wound healing with subsequent fibrosis may lead to obstruction of the created channel which frequently results in early surgical failure and consequent progression of visual field loss. Preoperative use of antimitotics, such as mitomycin-C and 5-fluorouracyl, effectively improves surgery outcome. However, the use of these nonspecific antiproliferative agents can be associated with severe side effects. This review provides an overview of the most important efforts that have been made to explore novel, more specific, and safer agents to prevent glaucoma filtration failure and improve surgery outcome.
青光眼是一种神经退行性疾病，是不可逆性失明的第二大重要原因。滤过性手术仍然是降低青光眼患者眼压的最有效疗法。长期手术成功的主要决定因素是愈合反应。术后过度的伤口愈合及随后的纤维化可能导致所创建通道的阻塞，这常常导致早期手术失败以及随之而来的视野丧失进展。术前使用抗有丝分裂剂，如丝裂霉素-C和5-氟尿嘧啶，可有效改善手术效果。然而，使用这些非特异性抗增殖剂可能会伴有严重的副作用。本综述概述了为探索新型、更具特异性且更安全的药物以预防青光眼滤过失败并改善手术效果所做的最重要努力。
